Giardiasis
Conditions
Interventions
Group I (Experimental): Mebendazole 200 mg by oral route three times during three days, (64 patients). Group II (Control): Secnidazole 2g by oral route in a single dose, a single day, (62 patients).
Sponsors
Central Military Hospital "Carlos J. Finlay"
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Informed-consent form signed. Patients with 18 years and older.
Exclusion criteria
Exclusion criteria: Patients who had previously received any antiparasitic drug within 1 month before entering the study. Have known about any hypersensitivity to any of the drugs in use. Have any immunodeficiency disease. Have any hepatic disease. Have any renal disease. Have any cardiovascular disease. Have any haematological disease. Have used other drugs joined to the drugs in use. Women were pregnant or lactation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Parasitological answer (Cured: If no Giardia cysts or trophozoites be found in any of the three post-treatment faecal simples, Not cured: Other case (microscopical examination as direct wet mount and Ritchie concentration. Measuring time: 3, 5 and 7 days after treatment completion. Clinical answer (Without clinical manifestations, with a relieve of the clinical manifestations, with the same clinical manifestations). Measuring time: 12 days after treatment completion. | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse Events (description of the events). Measuring time: 3 days after treatment completion. Intensity of AE (Slight, moderate or severe, taking into account the grade of disfunction produced by the event). Measuring time: 3 days after treatment completion. | — |
Countries
Cuba
Contacts
Public ContactPedro Almirall Carbonell
Faculty of Medical Sciences "Comandante Manuel Fajardo"
Outcome results
None listed